EUVIMEDEUVIMED entdecken
Crossref

Preliminary (12 weeks) Results from trial of Denosumab for Acute Charcot Neuroarthropathy

Namson S. Lau, Matthew Malone, Hugh Grant Dickson

UNSWorks (University of New South Wales, Sydney, Australia) · 06.08.2025

DOI: 10.26190/unsworks/31431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UNSWorks (University of New South Wales, Sydney, Australia), erschienen am 06.08.2025. Verfasst von Namson S. Lau und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Clinical Features & Outcomes Charcot Neuroarthropathy (CN) can affect any joint, but in people with diabetes it mostly affects feet and ankles * Active CN typically presents as a warm, swollen & hot foot, often but not always following a precipitating injury * If unrecognised or under treated, progressive inflammation, swelling and foot deformity develops * CN is associated with increased rates of foot infection, osteomyelitis, lower limb amputation and CVD related death * Recruitment & data collection is continuing (target n = 36) * However as preliminary results are promising and as effect size larger than originally anticipated interim analysis at n = 15 completers * Above needed to inform placebo controlled randomised clinical trial, which is necessary to validate findings CONCLUSIONS * Charcot Neuroarthropathy (CN) is an uncommon but under recognised and potentially devastating form of diabetic foot disease (DFD) * Current treatments are both costly & complex while not addressing underlying disease processes * Research into CN is challenging but need is clear * The preliminary results from our trial of denosumab for active CN indicates a positive effect on CN disease activity * These promising results, if validated, could have a significant impact on the clinical outcomes and health care costs for a costly form of DFD The authors gratefully acknowledge project funding from Diabetes Australia

Schlagwörter

Charcot footdenosumabdiabetic footdisease activityosteoclast inhibitionfoot deformityosteomyelitisamputation preventionRANKL inhibitor

Zitieren

APA

Lau, N. S., Malone, M., & Dickson, H. G. (2025). Preliminary (12 weeks) Results from trial of Denosumab for Acute Charcot Neuroarthropathy. UNSWorks (University of New South Wales, Sydney, Australia). https://doi.org/10.26190/unsworks/31431

Vancouver

Lau NS, Malone M, Dickson HG. Preliminary (12 weeks) Results from trial of Denosumab for Acute Charcot Neuroarthropathy. UNSWorks (University of New South Wales, Sydney, Australia). 2025. doi:10.26190/unsworks/31431

BibTeX
@article{Lau2025,
  author = {Lau, Namson S. and Malone, Matthew and Dickson, Hugh Grant},
  title = {Preliminary (12 weeks) Results from trial of Denosumab for Acute Charcot Neuroarthropathy},
  journal = {UNSWorks (University of New South Wales, Sydney, Australia)},
  year = {2025},
  doi = {10.26190/unsworks/31431}
}
Kostenlos starten →